Evotec and Shionogi Enter Fragment-based Drug Discovery Alliance

Tuesday, 05. October 2010 07:30
Evotec AG /
Evotec and Shionogi Enter Fragment-based Drug Discovery Alliance
Processed and transmitted by Thomson Reuters.
The issuer is solely responsible for the content of this announcement.

Hamburg, Germany - 05 October 2010: Evotec AG (Frankfurt Stock Exchange: EVT,
TecDAX) today announced that it has entered into a multiple target drug
discovery collaboration with Shionogi & Co Ltd. (Tokyo and Osaka Stock
Exchanges: 4507), to identify small molecule modulators of various protein-
protein interaction targets.

Evotec will apply its proprietary and integrated fragment-based drug discovery
platform, EVOlution(TM) to the programme. The key benefit of this platform for
the selection of target-specific strategies is its versatility, combining
biochemical and biophysical techniques including nuclear magnetic resonance
(NMR), surface plasmon resonance (SPR) and X-ray crystallography. Within this
collaboration, EVOlution(TM) will be used to investigate protein-protein
interactions on targets selected by Shionogi.

Dr Mario Polywka, COO of Evotec stated: "We are extremely pleased that Shionogi
has decided to undertake these projects with Evotec. Our proprietary fragment-
based drug discovery platform has shown that it adds significant value to our
partner's programmes and we look forward to supporting Shionogi in finding novel
treatments for inflammation and infectious diseases."

No financial details are disclosed.

About EVOlution(TM
)EVOlution(TM) is Evotec's fragment-based drug discovery platform which combines
biochemical and biophysical techniques including nuclear magnetic resonance
(NMR), surface plasmon resonance (SPR) and X-ray crystallography for the
screening of low molecular weight compounds and fragments. By the combination of
the orthogonal screening technologies, Evotec's fragment screening platform is
capable of screening a more diverse set of biological targets than other
fragment screening approaches, as well as being able to screen the fragments in
a high-throughput mode. The benefit of this is the ability to identify active
fragments for numerous classes of biological targets in a short space of time.
For further information, please see: www.evotec.com/fragment-based drug

About Fragment-based Drug Discovery
Fragment-based drug discovery (FBDD) is a drug discovery strategy that utilises
very small molecules - fragments of more complex molecules - to generate
efficient starting points for drug discovery. This approach thus provides the
opportunity to effectively manage the molecular weight and overall complexity of
drug candidates, a recognised success factor in drug development.

About Evotec AG
Evotec is a leader in the discovery and development of novel small molecule
drugs with operational sites in Europe and Asia. The Company has built
substantial drug discovery expertise and an industrialised platform that can
drive new innovative small molecule compounds into the clinic. In addition,
Evotec has built a deep internal knowledge base in the treatment of diseases
related to neuroscience, pain, oncology, inflammation and metabolic diseases.
Leveraging these skills and expertise the Company intends to develop best-in-
class differentiated therapeutics and deliver superior science-driven discovery
alliances with pharmaceutical and biotechnology companies. Evotec has long-term
discovery alliances with partners including Boehringer Ingelheim, CHDI,
Genentech, Novartis, Ono Pharmaceutical and Roche. Evotec has product candidates
in clinical development and a series of preclinical compounds and development
partnerships, including for example a strategic alliance with Roche for the EVT
100 compound family, subtype selective NMDA receptor antagonists for use in
treatment-resistant depression and an alliance in the field of diabetes with
Andromeda (Teva). For additional information please go towww.evotec.com.

Contact: Dr Werner Lanthaler, Chief Executive Officer,
Evotec AG, Tel.: +49.(0)40.56081-242, werner.lanthaler@evotec.com

Forward-Looking Statements - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. Such forward-looking statements include, but are not limited to,
statements about our 2010 financial outlook and our expected financial results
in future quarters, our revised revenue guidance for 2010 and expected revenue
growth, our ability to deliver on our liquidity guidance, our belief that we are
on course to sustainable profitability latest in 2012, our expectations and
assumptions concerning regulatory, clinical and business strategies, the
progress of our clinical development programmes and timing of the commencement
and results of our clinical trials, strategic collaborations and management's
plans, objectives and strategies. These statements are neither promises nor
guarantees, but are subject to a variety of risks and uncertainties, many of
which are beyond our control, and which could cause actual results to differ
materially from those contemplated in these forward-looking statements. In
particular, the risks and uncertainties include, among other things: risks that
product candidates may fail in the clinic or may not be successfully marketed or
manufactured; the risk that we will not achieve the anticipated benefits of our
collaborations, partnerships and acquisitions in the timeframes expected, or at
all; risks relating to our ability to advance the development of product
candidates currently in the pipeline or in clinical trials; our inability to
further identify, develop and achieve commercial success for new products and
technologies; the risk that competing products may be more successful; our
inability to interest potential partners in our technologies and products; our
inability to achieve commercial success for our products and technologies; our
inability to protect our intellectual property and the cost of enforcing or
defending our intellectual property rights; our failure to comply with
regulations relating to our products and product candidates, including FDA
requirements; the risk that the FDA may interpret the results of our studies
differently than we have; the risk that clinical trials may not result in
marketable products; the risk that we may be unable to successfully secure
regulatory approval of and market our drug candidates; and risks of new,
changing and competitive technologies and regulations in the U.S. and
The list of risks above is not exhaustive. Our most recent Annual Report on Form
20-F, filed with the Securities and Exchange Commission, and other documents
filed with, or furnished to the Securities and Exchange Commission, contain
additional factors that could impact our businesses and financial performance.
We expressly disclaim any obligation or undertaking to release publicly any
updates or revisions to any such statements to reflect any change in our
expectations or any change in events, conditions or circumstances on which any
such statement is based.


--- End of Message ---

Evotec AG
Schnackenburgallee 114 Hamburg Germany

WKN: 566480;ISIN: DE0005664809;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;

Pdf of Press Release:

This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Evotec AG via Thomson Reuters ONE
Related Links: Evotec SE
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.